Bioxtreme Receives Strategic Investment From Serra Holding

The company, which has raised $15 million so far, plans to use the funds to expand globally, strengthen its operations in the U.S. and Europe, and support the launch of Plaxtreme.

Plaxtreme is designed to help restore hand movement. It combines precision robotics, virtual environments, and Bioxtreme’s error-augmentation technology to improve grasp and release, speed up recovery, and enhance overall results for users. Key features include:

Plaxtreme includes patented error-augmentation technology that increases movement errors to help the brain learn faster and improve accuracy, along with AI-based adaptive learning that analyzes performance in real time and adjusts therapy to support progress.

It also supports natural forearm rotation to improve coordination for daily tasks through interactive 3D and gamified activities that encourage repeated practice. The system provides real time visual feedback, and automatically adjusts difficulty based on the user’s ability, while being designed for easy clinical use with quick setup, simple operation and smooth transitions for therapists.

Bioxtreme’s portfolio also includes Dextreme™, an advanced robotic system for upper-limb rehabilitation. It uses adaptive error-augmentation technology to speed up motor learning and help patients regain functional independence.

Read More:Nephronomics Receives Investment From CerraCap

“Bioxtreme is entering an exciting phase of growth as we expand both our leadership team and our scientific foundation,” said Eyal Samuel Shachar, CEO of Bioxtreme. “With new investment from Serra Holding, the addition of world-class scientific advisors, and the launch of Plaxtreme, we are strengthening our ability to translate cutting-edge neuroscience into rehabilitation solutions where error becomes independence, impacting the lives of patients who need it most. We’re excited for this next step in the company’s growth.”  

About Bioxtreme

Founded in 2010 Bioxtreme develops robotic systems for hand and upper limb rehabilitation for people with neurological conditions such as stroke. Its technology combines AI with its unique Error Augmentation (EA) method to apply adaptive forces that help patients learn movements faster, and improve accuracy. By leveraging advanced robotics, real time data and interactive therapy, Bioxtreme aims to accelerate recovery and improve patient outcomes.

Read More:Octen Closes $10M Seed Funding Round